Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
April 15, 2025
Alkermes’ Statement on the Passing of Iain Brown, Chief Financial Officer
April 01, 2025
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Responsible Growth
Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices.
Culture of Excellence
Our employees' dedication to patients and our communities is foundational to our culture. Hear how our team members contribute to building an organization dedicated to creating real impact.
Notable Recognition
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes, based on the results of a third-party survey shared with our U.S.-based employees.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
OverviewOlanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Clinical TrialsOlanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
ALKS 2680
-
Narcolepsy Type 1
Phase 2
-
Narcolepsy Type 2
Phase 2
-
Idiopathic Hypersomnia
Phase 2
OverviewALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Clinical TrialsALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, Vibrance-2, a phase 2 study in adults with narcolepsy type 2, and Vibrance-3, a phase 2 study in adults with idiopathic hypersomnia. Participants who complete one of the Vibrance studies have the option to continue in a long-term, open-label, safety study evaluating the safety of ALKS 2680 for up to two years.
For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:- Vibrance-1: clinicaltrials.gov/study/NCT06358950
- Vibrance-2: clinicaltrials.gov/study/NCT06555783
- Vibrance-3: clinicaltrials.gov/study/NCT06843590
-
-
ALKS 4510
-
Neuroscience Indications
Preclinical
OverviewALKS 4510 is an investigational orexin 2 receptor agonist being evaluated preclinically for the treatment of central nervous system disorders.
-
-
ALKS 7290
-
Neuroscience Indications
Preclinical
OverviewALKS 7290 is an investigational orexin 2 receptor agonist being evaluated preclinically for the treatment of central nervous system disorders.
-
